Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
28
AVXL Quote, Financials, Valuation and Earnings
Last price:
$4.10
Seasonality move
:
12.08%
Day range:
$3.82 - $4.26
52-week range:
$2.86 - $13.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.86x
Volume:
1.7M
Avg. volume:
1.6M
1-year change:
-52.82%
Market cap:
$366.3M
Revenue:
--
EPS (TTM):
-$0.54
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AVXL
Anavex Life Sciences Corp.
|
-- | -$0.11 | -- | -12.61% | $22.00 |
|
ANAB
AnaptysBio, Inc.
|
$87.1M | $0.93 | -26.24% | -13.87% | $67.92 |
|
CRMD
CorMedix, Inc.
|
$127M | $0.81 | 178.34% | 90.44% | $14.86 |
|
OCGN
Ocugen, Inc.
|
$860K | -$0.06 | -66.24% | -14.07% | $9.00 |
|
REPL
Replimune Group, Inc.
|
-- | -$0.82 | -- | -21.85% | $12.86 |
|
VSTM
Verastem, Inc.
|
$16.9M | -$0.48 | -88.84% | -63.78% | $16.63 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AVXL
Anavex Life Sciences Corp.
|
$4.10 | $22.00 | $366.3M | -- | $0.00 | 0% | -- |
|
ANAB
AnaptysBio, Inc.
|
$49.73 | $67.92 | $1.4B | -- | $0.00 | 0% | 8.72x |
|
CRMD
CorMedix, Inc.
|
$7.69 | $14.86 | $605.9M | 3.75x | $0.00 | 0% | 2.59x |
|
OCGN
Ocugen, Inc.
|
$1.33 | $9.00 | $435.3M | -- | $0.00 | 0% | 73.00x |
|
REPL
Replimune Group, Inc.
|
$7.75 | $12.86 | $639.9M | -- | $0.00 | 0% | -- |
|
VSTM
Verastem, Inc.
|
$6.67 | $16.63 | $502.4M | -- | $0.00 | 0% | 31.17x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AVXL
Anavex Life Sciences Corp.
|
-- | -0.091 | -- | 11.47x |
|
ANAB
AnaptysBio, Inc.
|
109.28% | 0.036 | 41.03% | 8.52x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.679 | 0.48% | 1.60x |
|
OCGN
Ocugen, Inc.
|
90.32% | 2.109 | 6.48% | 1.60x |
|
REPL
Replimune Group, Inc.
|
26.61% | 1.818 | 9.86% | 5.37x |
|
VSTM
Verastem, Inc.
|
121% | -1.406 | 15.18% | 2.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AVXL
Anavex Life Sciences Corp.
|
-- | -$10.8M | -44.87% | -44.87% | -- | -$8.6M |
|
ANAB
AnaptysBio, Inc.
|
$75.7M | $34.7M | -22.38% | -367.62% | 45.47% | -$27.4M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
OCGN
Ocugen, Inc.
|
$802K | -$17.6M | -139.38% | -345.08% | -1005.99% | -$13M |
|
REPL
Replimune Group, Inc.
|
-$1.6M | -$72.2M | -75.32% | -92.13% | -- | -$66.1M |
|
VSTM
Verastem, Inc.
|
$9.3M | -$40.7M | -369.69% | -1773.4% | -362.17% | -$44.5M |
Anavex Life Sciences Corp. vs. Competitors
-
Which has Higher Returns AVXL or ANAB?
AnaptysBio, Inc. has a net margin of -- compared to Anavex Life Sciences Corp.'s net margin of 19.8%. Anavex Life Sciences Corp.'s return on equity of -44.87% beat AnaptysBio, Inc.'s return on equity of -367.62%.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences Corp.-- -$0.11 $94.9M ANABAnaptysBio, Inc.99.2% $0.52 $317M -
What do Analysts Say About AVXL or ANAB?
Anavex Life Sciences Corp. has a consensus price target of $22.00, signalling upside risk potential of 436.59%. On the other hand AnaptysBio, Inc. has an analysts' consensus of $67.92 which suggests that it could grow by 36.57%. Given that Anavex Life Sciences Corp. has higher upside potential than AnaptysBio, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than AnaptysBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences Corp.2 1 0 ANABAnaptysBio, Inc.9 1 0 -
Is AVXL or ANAB More Risky?
Anavex Life Sciences Corp. has a beta of 1.212, which suggesting that the stock is 21.178% more volatile than S&P 500. In comparison AnaptysBio, Inc. has a beta of 0.354, suggesting its less volatile than the S&P 500 by 64.645%.
-
Which is a Better Dividend Stock AVXL or ANAB?
Anavex Life Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AnaptysBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences Corp. pays -- of its earnings as a dividend. AnaptysBio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or ANAB?
Anavex Life Sciences Corp. quarterly revenues are --, which are smaller than AnaptysBio, Inc. quarterly revenues of $76.3M. Anavex Life Sciences Corp.'s net income of -$9.8M is lower than AnaptysBio, Inc.'s net income of $15.1M. Notably, Anavex Life Sciences Corp.'s price-to-earnings ratio is -- while AnaptysBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences Corp. is -- versus 8.72x for AnaptysBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences Corp.-- -- -- -$9.8M ANABAnaptysBio, Inc.8.72x -- $76.3M $15.1M
-
Which has Higher Returns AVXL or CRMD?
CorMedix, Inc. has a net margin of -- compared to Anavex Life Sciences Corp.'s net margin of 49.9%. Anavex Life Sciences Corp.'s return on equity of -44.87% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences Corp.-- -$0.11 $94.9M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About AVXL or CRMD?
Anavex Life Sciences Corp. has a consensus price target of $22.00, signalling upside risk potential of 436.59%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 93.2%. Given that Anavex Life Sciences Corp. has higher upside potential than CorMedix, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than CorMedix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences Corp.2 1 0 CRMDCorMedix, Inc.4 0 0 -
Is AVXL or CRMD More Risky?
Anavex Life Sciences Corp. has a beta of 1.212, which suggesting that the stock is 21.178% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.
-
Which is a Better Dividend Stock AVXL or CRMD?
Anavex Life Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences Corp. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or CRMD?
Anavex Life Sciences Corp. quarterly revenues are --, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Anavex Life Sciences Corp.'s net income of -$9.8M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Anavex Life Sciences Corp.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences Corp. is -- versus 2.59x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences Corp.-- -- -- -$9.8M CRMDCorMedix, Inc.2.59x 3.75x $104.3M $108.6M
-
Which has Higher Returns AVXL or OCGN?
Ocugen, Inc. has a net margin of -- compared to Anavex Life Sciences Corp.'s net margin of -1144.46%. Anavex Life Sciences Corp.'s return on equity of -44.87% beat Ocugen, Inc.'s return on equity of -345.08%.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences Corp.-- -$0.11 $94.9M OCGNOcugen, Inc.45.78% -$0.07 $36.5M -
What do Analysts Say About AVXL or OCGN?
Anavex Life Sciences Corp. has a consensus price target of $22.00, signalling upside risk potential of 436.59%. On the other hand Ocugen, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 576.69%. Given that Ocugen, Inc. has higher upside potential than Anavex Life Sciences Corp., analysts believe Ocugen, Inc. is more attractive than Anavex Life Sciences Corp..
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences Corp.2 1 0 OCGNOcugen, Inc.4 0 0 -
Is AVXL or OCGN More Risky?
Anavex Life Sciences Corp. has a beta of 1.212, which suggesting that the stock is 21.178% more volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 3.493, suggesting its more volatile than the S&P 500 by 249.3%.
-
Which is a Better Dividend Stock AVXL or OCGN?
Anavex Life Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences Corp. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or OCGN?
Anavex Life Sciences Corp. quarterly revenues are --, which are smaller than Ocugen, Inc. quarterly revenues of $1.8M. Anavex Life Sciences Corp.'s net income of -$9.8M is higher than Ocugen, Inc.'s net income of -$20.1M. Notably, Anavex Life Sciences Corp.'s price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences Corp. is -- versus 73.00x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences Corp.-- -- -- -$9.8M OCGNOcugen, Inc.73.00x -- $1.8M -$20.1M
-
Which has Higher Returns AVXL or REPL?
Replimune Group, Inc. has a net margin of -- compared to Anavex Life Sciences Corp.'s net margin of --. Anavex Life Sciences Corp.'s return on equity of -44.87% beat Replimune Group, Inc.'s return on equity of -92.13%.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences Corp.-- -$0.11 $94.9M REPLReplimune Group, Inc.-- -$0.77 $286.9M -
What do Analysts Say About AVXL or REPL?
Anavex Life Sciences Corp. has a consensus price target of $22.00, signalling upside risk potential of 436.59%. On the other hand Replimune Group, Inc. has an analysts' consensus of $12.86 which suggests that it could grow by 65.9%. Given that Anavex Life Sciences Corp. has higher upside potential than Replimune Group, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than Replimune Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences Corp.2 1 0 REPLReplimune Group, Inc.4 2 0 -
Is AVXL or REPL More Risky?
Anavex Life Sciences Corp. has a beta of 1.212, which suggesting that the stock is 21.178% more volatile than S&P 500. In comparison Replimune Group, Inc. has a beta of 0.727, suggesting its less volatile than the S&P 500 by 27.342%.
-
Which is a Better Dividend Stock AVXL or REPL?
Anavex Life Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Replimune Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences Corp. pays -- of its earnings as a dividend. Replimune Group, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or REPL?
Anavex Life Sciences Corp. quarterly revenues are --, which are smaller than Replimune Group, Inc. quarterly revenues of --. Anavex Life Sciences Corp.'s net income of -$9.8M is higher than Replimune Group, Inc.'s net income of -$70.9M. Notably, Anavex Life Sciences Corp.'s price-to-earnings ratio is -- while Replimune Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences Corp. is -- versus -- for Replimune Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences Corp.-- -- -- -$9.8M REPLReplimune Group, Inc.-- -- -- -$70.9M
-
Which has Higher Returns AVXL or VSTM?
Verastem, Inc. has a net margin of -- compared to Anavex Life Sciences Corp.'s net margin of -876.34%. Anavex Life Sciences Corp.'s return on equity of -44.87% beat Verastem, Inc.'s return on equity of -1773.4%.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences Corp.-- -$0.11 $94.9M VSTMVerastem, Inc.82.57% -$1.35 $74M -
What do Analysts Say About AVXL or VSTM?
Anavex Life Sciences Corp. has a consensus price target of $22.00, signalling upside risk potential of 436.59%. On the other hand Verastem, Inc. has an analysts' consensus of $16.63 which suggests that it could grow by 149.25%. Given that Anavex Life Sciences Corp. has higher upside potential than Verastem, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than Verastem, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences Corp.2 1 0 VSTMVerastem, Inc.8 0 0 -
Is AVXL or VSTM More Risky?
Anavex Life Sciences Corp. has a beta of 1.212, which suggesting that the stock is 21.178% more volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.56%.
-
Which is a Better Dividend Stock AVXL or VSTM?
Anavex Life Sciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences Corp. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or VSTM?
Anavex Life Sciences Corp. quarterly revenues are --, which are smaller than Verastem, Inc. quarterly revenues of $11.2M. Anavex Life Sciences Corp.'s net income of -$9.8M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Anavex Life Sciences Corp.'s price-to-earnings ratio is -- while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences Corp. is -- versus 31.17x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences Corp.-- -- -- -$9.8M VSTMVerastem, Inc.31.17x -- $11.2M -$98.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
